Company news
Foresee Pharmaceuticals Co., Ltd. (TPEX:6576) news
Foresee Pharmaceuticals Co., Ltd. news releases on 6ix. Latest, Jul 9, 2026: Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer…
Press releases & updates
Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty
July 9, 2026
Foresee Pharmaceuticals Welcomes Positive CHMP Opinion Recommending Approval of CAMCEVI 21mg, 3-month strength in the European Union for Advanced Prostate Cancer
March 6, 2026
Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP)
February 4, 2026
Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC
January 8, 2026
Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide mesylate
December 24, 2025
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer
August 27, 2025
Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectable Products
August 12, 2024
Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of CPP
April 2, 2024
Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease
October 31, 2023
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium
October 2, 2023
Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications
October 2, 2023
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing
June 28, 2023
Foresee Pharmaceuticals Presented Poster on MMP-12 inhibitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases
June 22, 2023
Foresee Pharmaceuticals : will attend the investor conference held by Cathay Securities Corporation
August 15, 2022
Foresee Pharmaceuticals : The submission of an IND for FP-045 in patients with Fanconi anemia by TRPharm to the Ministry of Health of Turkey
August 10, 2022
Foresee Pharmaceuticals : Board of Directors resolved to approve the 2022Q2 consolidated financial report
August 8, 2022
Foresee Pharmaceuticals : announces phase 2 results of FP-025 in patients with Covid-19 associated ARDS
August 2, 2022
Foresee Pharmaceuticals : The Submission of CAMCEVI 42 mg Marketing Authorization Application by Accord Healthcare, Foresee's Licensing Partner, to the MHRA of the UK
July 26, 2022
Foresee Pharmaceuticals : announces the submission of a phase 3 IND to US FDA for FP-001 42 mg in patients with central precocious puberty
July 20, 2022
Foresee Pharmaceuticals : announces the submission of New Drug Application for CAMCEVI 42 mg to TFDA
June 9, 2022
Foresee Pharmaceuticals : announces EMA approval of CAMCEVI 42 mg for the treatment of advanced prostate cancer
May 30, 2022
Foresee Pharmaceuticals : will attend the 11th Taiwan CEO Week held by Taiwan Stock Exchange and QIC
April 18, 2022
Foresee Pharmaceuticals : The submission of Marketing Authorization Application by Megapharm for CAMCEVI 42 mg to the Ministry of Health of Israel
April 5, 2022
Foresee Pharmaceuticals : CAMCEVI 42 mg Injection Emulsion launched in the U.S. for the Treatment of Advanced Prostate Cancer
April 4, 2022
Foresee Pharmaceuticals : received positive CHMP opinion for CAMCEVI 42 mg for the treatment of advanced prostate cancer
March 24, 2022